

Stratech

stratech.co.uk/signalchem info@stratech.co.uk

Anti-2019-nCoV Spike Protein Neutralizing Nanobody (NBX20014)

Catalog No: C19S1-654L

SARS-CoV-2 variants with critical mutations on its Spike protein RBD, which facilitates viral entry into the host cells by effective binding to the human ACE2 receptor are responsible for a recent spike in the global COVID19 cases. Variants evading the neutralizing antibodies produce substantial challenges in controlling the SARS-CoV-2 infections. Camelid Nanobodies are single-domain heavy chain antibodies effective in neutralizing these new variants by targeting the novel mutated RBD epitopes. SignalChem's recombinant llama VHH antibody have been raised in llama for studying neutralization of SARS-CoV-2 and detection of 2019 -nCoV Spike Protein.

Unique Selling Points



Detects 2019 n-CoV Spike Protein Neutralizing activity validated

for wild type & N501Y variant



Fully functional antibody



Neutralizing activity validated for (K417N, E484K, N501Y) RBD.

Competitors







Biopharma developing Anti-SARS-CoV-2 therapies

University researchers studying SARS-CoV-2 neutralization

Target Customers



Scientists developing

diagnostic tests



Biotech companies

developing vaccines



Government research organizations



Anti 2019-nCoV Spike Protein Neutralizing Nanobody (NBX20014)

Catalog No: C19S1-644HL

Infection of SARS-CoV-2 is mediated by the binding of its spike trimeric glycoprotein (S) to the host receptor angiotensin-converting enzyme 2 (ACE2). Recent mutations in the viral (S) protein have created the new circulating variants of SARS-CoV-2 enhancing ACE2 binding, and elude many neutralizing mAbs. Camelid VHH single-domain antibodies, or nanobodies, (Nbs) are substantially smaller Compared to mAbs yet can bind to the virus antigens with excellent epitope specificity. SignalChem's recombinant llama VHH-Human IgG Antibody are excellent candidates to study neutralization of SARS-CoV-2 and detection of 2019 -nCoV Spike Protein.

Applications







COVID19 ELISAs

Nanobody based Therapies R&D

COVID19 Protein Arrays





Diagnostic kits R&D

Vaccine Research





Binding ability measured in a functional ELISA. Anti 2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-644HL) binds 2019-nCoV Spike protein RBD.



Inhibitory activity of Anti 2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-644HL) against 2019-nCoV RBD binding to ACE2(19-740) protein determined by ELISA.